Supernus Pharmaceuticals, Inc.
SUPN· Nasdaq
SUPNSupernus Pharmaceuticals, Inc.
Filed Mar 9, 2023 · 10-K · 68 days after period end · 0001356576-23-000016
derived · Computed from the longer spans the company filed.
| Metric | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 |
|---|---|---|---|---|
| Revenue | $167.33M | $159.05M | $143.56M | $100.45M |
| Net Income | $25.48M | $2.44M | $30.77M | $33.13M |
| EPS Diluted | — | — |
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
| — |
| $0.62 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2022 · filed Mar 9, 2023 · 68 d after period end
